Done Health (often styled as “Done.”) launched in 2020 as a telehealth platform specifically focused on ADHD — a condition that affects an estimated 10 million adults in the US, many of whom remain undiagnosed or undertreated.
The platform’s pitch is straightforward: complete an online assessment, get matched with a licensed clinician, attend a video evaluation, and if diagnosed, receive a prescription and ongoing medication management. The entire process can happen within days, compared to the months-long wait times common for in-person ADHD specialists.
Done operates on a membership model, charging roughly $199 for an initial evaluation and $79/month for ongoing care that includes follow-up appointments, prescription management, and messaging access to providers. The company doesn’t accept insurance directly but provides superbills for potential reimbursement.
The company grew rapidly during the pandemic-era telehealth boom but faced significant challenges. In 2022, Done came under scrutiny from the DOJ and DEA over concerns about overprescribing controlled stimulant medications. The company’s CEO was charged in a federal case related to prescribing practices. Done responded by implementing stricter clinical protocols and compliance measures.
Despite the controversy, Done Health continues to operate and serve patients. The platform highlights that ADHD remains severely underdiagnosed, particularly in women and adults who were missed during childhood. For patients in areas without accessible ADHD specialists — which describes most of rural America — telehealth services like Done represent one of the few paths to evaluation and treatment.
The company’s story reflects broader tensions in telehealth: the balance between access and appropriate prescribing safeguards.
